75 related articles for article (PubMed ID: 9543121)
1. Calcimimetics--new drugs with the potential to control hyperparathyroidism.
Ott SM
J Clin Endocrinol Metab; 1998 Apr; 83(4):1080-2. PubMed ID: 9543121
[No Abstract] [Full Text] [Related]
2. Nonoperative management of hyperparathyroidism: present and future.
Weigel RJ
Curr Opin Oncol; 2001 Jan; 13(1):33-8. PubMed ID: 11148683
[TBL] [Abstract][Full Text] [Related]
3. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
4. The role of estrogens and related compounds in the management of primary hyperparathyroidism.
Marcus R
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N146-9. PubMed ID: 12412792
[No Abstract] [Full Text] [Related]
5. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type Ib.
Tollin SR; Perlmutter S; Aloia JF
J Bone Miner Res; 2000 Jul; 15(7):1412-6. PubMed ID: 10893692
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic use of calcimimetics.
Hebert SC
Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
[TBL] [Abstract][Full Text] [Related]
7. Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism.
Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE
Horm Metab Res; 1994 Jan; 26(1):39-42. PubMed ID: 8150422
[TBL] [Abstract][Full Text] [Related]
8. [Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism].
Tominaga Y
Clin Calcium; 2008 Jan; 18(1):67-71. PubMed ID: 18175874
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
10. [Clinical use of calcimimetics in the treatment of hyperparathyroidisms].
Urena P
Med Sci (Paris); 2004 Nov; 20(11):973-8. PubMed ID: 15525492
[TBL] [Abstract][Full Text] [Related]
11. Calcimimetics and calcilytics--fooling the calcium receptor.
Steddon SJ; Cunningham J
Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
[TBL] [Abstract][Full Text] [Related]
12. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake.
Jorde R; Szumlas K; Haug E; Sundsfjord J
Eur J Nutr; 2002 Dec; 41(6):258-63. PubMed ID: 12474069
[TBL] [Abstract][Full Text] [Related]
13. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
[TBL] [Abstract][Full Text] [Related]
14. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.
Chow CC; Chan WB; Li JK; Chan NN; Chan MH; Ko GT; Lo KW; Cockram CS
J Clin Endocrinol Metab; 2003 Feb; 88(2):581-7. PubMed ID: 12574184
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
[TBL] [Abstract][Full Text] [Related]
16. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism.
Toro Prieto FJ; Bernal Blanco G; Navarro García M; Cabello Chaves V; Garcíajiménez R; Pereira Palomo P; Gentil Govantes MA
Transplant Proc; 2009; 41(6):2144-7. PubMed ID: 19715857
[TBL] [Abstract][Full Text] [Related]
17. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy.
McDermott MT; Perloff JJ; Kidd GS
J Bone Miner Res; 1994 Apr; 9(4):509-14. PubMed ID: 8030438
[TBL] [Abstract][Full Text] [Related]
18. [Calcimimetics as a new chance for effective treatment of calcium metabolism disturbances].
Nowak Z; Laudański K
Pol Merkur Lekarski; 2002 Nov; 13(77):424-7. PubMed ID: 12621766
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.
Keutgen XM; Buitrago D; Filicori F; Kundel A; Elemento O; Fahey TJ; Zarnegar R
Ann Surg; 2012 May; 255(5):981-5. PubMed ID: 22470074
[TBL] [Abstract][Full Text] [Related]
20. Vasculotropic effects of calcimimetics.
Koleganova N; Piecha G; Ritz E
Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):32-6. PubMed ID: 19816173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
